Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Brentuximab Vedotin Administered To Platinum-Refractory Transplant Naïve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status
Blood (2013)
  • Leona Holmberg, Fred Hutchinson Cancer Research Center
  • Andrei R. Shustov, Fred Hutchinson Cancer Research Center
  • Karen Schiavo, Fred Hutchinson Cancer Research Center
  • Arnp, Fred Hutchinson Cancer Research Center
  • Mary Philip, University of Washington
  • Edward N. Libby, Fred Hutchinson Cancer Research Center
  • Ryan D. Cassaday, Fred Hutchinson Cancer Research Center
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • David G. Maloney, Fred Hutchinson Cancer Research Center
  • Damian J. Green, Fred Hutchinson Cancer Research Center
  • Brian G. Till, Fred Hutchinson Cancer Research Center
  • Oliver W. Press, Fred Hutchinson Cancer Research Center
  • Ajay K. Gopal, Fred Hutchinson Cancer Research Center
Link
Disciplines
Publication Date
November 15, 2013
Citation Information
Leona Holmberg, Andrei R. Shustov, Karen Schiavo, Arnp, et al.. "Brentuximab Vedotin Administered To Platinum-Refractory Transplant Naïve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status" Blood Vol. 122 Iss. 21 (2013) p. 2106 - 2106
Available at: http://works.bepress.com/john-pagel/122/